2023
SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY
Kumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Sweed N, Dugan M, Kesari S. SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY. Neuro-Oncology Advances 2023, 5: iii20-iii20. PMCID: PMC10402348, DOI: 10.1093/noajnl/vdad070.077.Peer-Reviewed Original ResearchNon-small cell lung cancerUpper GI cancerHER2-negative primary tumorsAnti-HER2 therapyBreast cancer patientsLeptomeningeal metastasesNegative primary tumorsPrimary tumorHER2 amplificationGI cancersCancer patientsNSCLC patientsBreast cancerHER2-positive primary tumorsUpper GI cancer patientsCSF tumor cellsGI cancer patientsPositive primary tumorsCell lung cancerDiscretion of physiciansIT trastuzumabLM tumorsHER2 positivityNSCLC cancerLM patients
2022
BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASIS
Kumthekar P, Youssef M, Blondin N, Azadi A, Piccioni D, Glantz M, Carillo J, Sharma A, Avgeropoulos N, Makar S, Blouw B, Natasha A, Fisher D, Huynh L, Peters J, Matsutani M, Sales E, Sweed N, Dugan M, Kesari S. BIOM-05. THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH SOLID TUMOR LEPTOMENINGEAL METASTASIS. Neuro-Oncology 2022, 24: vii4-vii5. DOI: 10.1093/neuonc/noac209.015.Peer-Reviewed Original ResearchNon-small cell lung cancerUpper GI cancerLeptomeningeal metastasesHER2 amplificationPrimary tumorBreast cancerLM patientsGI cancersCancer patientsHER2-positive primary breast cancerHER2-positive primary tumorsSolid-tumor leptomeningeal metastasisUpper GI cancer patientsCSF tumor cellsGI cancer patientsPositive primary tumorsPrimary breast cancerBreast cancer patientsCell lung cancerIT trastuzumabLM tumorsNSCL cancerNSCLC patientsUpper GIClinical benefitCharacteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.
Buza N, Hui P. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma. Archives Of Pathology & Laboratory Medicine 2022, 146: 0. PMID: 35687792, DOI: 10.5858/arpa.2021-0547-oa.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaClinical trial criteriaHER2 gene amplificationTrial criteriaHER2 immunohistochemistrySerous carcinomaAnti-human epidermal growth factor receptor 2 (HER2) therapyClinical Oncology/CollegeHER2 testing algorithmHER2 FISHProspective clinical investigationHER2 IHC 2HER2/CEP17Gene amplificationContext of breastTherapeutic responseIHC 2HER2 amplificationAverage HER2Most tumorsClinical investigationImmunohistochemistryHER2 fluorescenceTumorsMonosomy 17
2021
Direct targeting of amplified gene loci for proapoptotic anticancer therapy
Kaushik Tiwari M, Colon-Rios DA, Tumu HCR, Liu Y, Quijano E, Krysztofiak A, Chan C, Song E, Braddock DT, Suh HW, Saltzman WM, Rogers FA. Direct targeting of amplified gene loci for proapoptotic anticancer therapy. Nature Biotechnology 2021, 40: 325-334. PMID: 34711990, PMCID: PMC8930417, DOI: 10.1038/s41587-021-01057-5.Peer-Reviewed Original ResearchConceptsDNA double-strand breaksTriplex-forming oligonucleotidesDNA damage responseDouble-strand breaksDrug resistanceGene amplificationP53-independent apoptosisHER2-positive breastOvarian cancer modelHuman tumor xenograftsInduction of apoptosisGenomic lociNumber of drugsCellular functionsDamage responseGene locusProtein productsHER2-positive cancer cellsDriver genesClinical efficacyCombat drug resistanceDNA damageHER2 amplificationTherapeutic strategiesTumor xenograftsDeep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer
Farahmand S, Fernandez AI, Ahmed FS, Rimm DL, Chuang JH, Reisenbichler E, Zarringhalam K. Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer. Modern Pathology 2021, 35: 44-51. PMID: 34493825, PMCID: PMC10221954, DOI: 10.1038/s41379-021-00911-w.Peer-Reviewed Original ResearchConceptsHER2 statusBreast cancerTreatment responseHER2-positive breast cancerAnti-HER2 agentsPre-treatment samplesNeoadjuvant chemotherapyTrastuzumab therapyClinical outcomesClinical evaluationProtein immunohistochemistryHER2 amplificationTrastuzumab responseTumor stainTreatment selectionTCGA testPathology teamTumor regionCancer featuresCancerPatientsHER2Current standardImmunohistochemistryHematoxylinSafety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies.
Schram A, Ahnert J, Patel M, Jauhari S, Sachdev J, Zhu V, LoRusso P, Nguyen D, Le X, O'Connor M, Waters N, Cook C, Witt K, Humphrey R, Janne P, Hamilton E. Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients (pts) with advanced solid malignancies. Journal Of Clinical Oncology 2021, 39: 3086-3086. DOI: 10.1200/jco.2021.39.15_suppl.3086.Peer-Reviewed Original ResearchFE cohortHER2 amplificationSolid tumorsHuman dose-escalation studyDose-escalation cohortsManageable safety profilePhase 2 doseAdvanced solid malignanciesAdvanced solid tumorsDose-escalation studyMetastatic solid tumorsPreliminary antitumor activityPhase 1 portionAnti-tumor activityTumor growth inhibitionBID cohortQD scheduleEGFR/HER2Adverse eventsEscalation cohortsPartial responseProgressive diseaseStandard therapySafety profilePreliminary efficacy
2020
Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome
Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PA, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ, Zhang C, Kaur N, Elmonshed D, Galletti G, Sarkar S, Bhinder B, Pittman ME, Plotnikova OM, Kotlov N, Frenkel F, Bagaev A, Elemento O, Betel D, Giannakakou P, Lenz HJ. Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome. Clinical Cancer Research 2020, 26: 4756-4766. PMID: 32641434, PMCID: PMC8209413, DOI: 10.1158/1078-0432.ccr-19-3920.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overEsophageal NeoplasmsEsophagogastric JunctionFemaleGene AmplificationGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleMiddle AgedProgression-Free SurvivalReceptor, ErbB-2Response Evaluation Criteria in Solid TumorsStomach NeoplasmsTaxoidsTumor-Associated MacrophagesConceptsProgression-free survivalMulticenter phase II studyPhase II studyPFS ratesII studyMacrophage signatureHER2 amplificationGastric cancerEfficacy targetAdvanced gastroesophageal cancerM2 macrophage signaturePrior taxane therapyCommon adverse eventsAdvanced gastric cancerMetastatic gastric cancerM2-like tumorImproved disease controlPrior therapyRECIST 1.1Taxane efficacyPrimary endpointTaxane therapyAdverse eventsGastroesophageal cancerMetastatic diseaseTargeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies.
Erickson BK, Zeybek B, Santin AD, Fader AN. Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. Current Opinion In Obstetrics & Gynecology 2020, 32: 57-64. PMID: 31833974, PMCID: PMC7307693, DOI: 10.1097/gco.0000000000000599.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Uterine serous carcinomaGynecologic malignanciesFactor receptor 2Serous carcinomaReceptor 2Recurrent uterine serous carcinomaAnti-HER2 antibody trastuzumabHER2-positive diseaseAnti-HER2 therapyAnti-HER2 treatmentHER2-positive breastTrial of womenEndometrial cancer subtypesMore treatment optionsEffective therapeutic targetTreatment optionsUterine carcinosarcomaTrastuzumab efficacyHER2 amplificationTargeted therapyGastric cancerSignificant efficacy
2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Annals Of Oncology 2019, 30: 927-933. PMID: 30903140, PMCID: PMC6594453, DOI: 10.1093/annonc/mdz076.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsClass I Phosphatidylinositol 3-KinasesFemaleFollow-Up StudiesGene AmplificationHumansIn Situ Hybridization, FluorescenceLapatinibNeoadjuvant TherapyPhosphatidylinositol 3-KinasesPrognosisReceptor, ErbB-2Remission InductionTrastuzumabConceptsPathologic complete responsePI3K pathway statusBreast cancerHER2 ratioPI3K pathwayNeoadjuvant lapatinibComplete responseHER2 amplificationPathway statusHER2-positive breast cancerPI3K pathway alterationsHER2 amplification levelHER2 FISH ratioK pathwayAnti-HER2 therapyWild-type PIK3CAPI3K pathway activationPIK3CA mutationsClinical subtypesHER2 overexpressionFISH ratioPatientsChemotherapyHER2High PTEN
2018
Gastric Carcinomas With Lymphoid Stroma
Hissong E, Ramrattan G, Zhang P, Zhou X, Young G, Klimstra D, Shia J, Fernandes H, Yantiss R. Gastric Carcinomas With Lymphoid Stroma. The American Journal Of Surgical Pathology 2018, 42: 453-462. PMID: 29438172, DOI: 10.1097/pas.0000000000001018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBiopsyCarcinomaDNA Mismatch RepairFemaleGenetic Predisposition to DiseaseHerpesvirus 4, HumanHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryIn Situ HybridizationLymphocytes, Tumor-InfiltratingMaleMicrosatellite InstabilityMiddle AgedMutationPhenotypeRetrospective StudiesRNA, ViralStomach NeoplasmsStromal CellsConceptsPD-L1 expressionEpstein-Barr virusLymphoid stromaGastric carcinomaPD-L1Frequent PD-L1 expressionSusceptible to checkpoint inhibitorsConventional gastric cancerTumor-infiltrating lymphocytesTumor mutational burdenEBV-encoded RNASubgroup of tumorsComprehensive Cancer PanelSpectrum of molecular changesCancer Genome Atlas studyEvaluated molecular alterationsIn situ hybridizationMismatch repair statusCheckpoint inhibitorsCancer Genome Atlas datasetHER2 amplificationInfiltrating lymphocytesGlandular differentiationKRAS alterationsTP53 variants
2017
GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma
Bivin W, Yergiyev O, Bunker M, Silverman J, Krishnamurti U. GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2017, 25: 553-558. PMID: 26945445, DOI: 10.1097/pai.0000000000000349.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaHER2 amplificationHER2 overexpressionER negativityPathologic stageHistologic gradeP53 positivityGRB7 expressionBreast cancerBreast carcinomaInvasive breast cancer correlatesInvasive breast cancerBreast cancer correlatesChromosome 17 copy numberAntiestrogen therapyPR expressionPredictive factorsHER2 expressionCancer correlatesPR testingP53 immunohistochemistryAggressive phenotypeHER2 geneHER2P53 status
2014
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2
Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical & Experimental Metastasis 2014, 32: 29-38. PMID: 25398397, PMCID: PMC4310789, DOI: 10.1007/s10585-014-9688-8.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAnimalsAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityAntineoplastic AgentsCarcinosarcomaCell Line, TumorCell ProliferationFemaleImmunoconjugatesM Phase Cell Cycle CheckpointsMaytansineMiceMice, SCIDOvarian NeoplasmsReceptor, ErbB-2TrastuzumabUterine NeoplasmsXenograft Model Antitumor AssaysConceptsCS cell linesT-DM1Cell linesFlow cytometryNovel antibody-drug conjugateAggressive clinical behaviorNovel treatment optionsG2/M phase cell cycle arrestHER2 protein overexpressionM phase cell cycle arrestPhase cell cycle arrestAntibody-drug conjugatesDisease refractoryPrimary HER2Vehicle miceOvarian carcinosarcomaPoor prognosisUterine carcinosarcomaCS patientsTreatment optionsClinical behaviorLonger survivalCell cycle arrestHER2 amplificationCarcinosarcomaA Targeted Next‐Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice
Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A Targeted Next‐Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. The Oncologist 2014, 19: 453-458. PMID: 24710307, PMCID: PMC4012963, DOI: 10.1634/theoncologist.2013-0377.Peer-Reviewed Original ResearchConceptsBreast cancerGenomic alterationsV-akt murine thymoma viral oncogene homolog 1Stage IV cancerMetastatic breast cancerActionable genomic alterationsPotential treatment optionOncogene homolog 1Primary tumor biopsiesCancer-related genesClinical Laboratory Improvement AmendmentsDependent kinasesMedian sequencing depthGene fusionsSequencing depthBase substitutionsHER2 mutationsHomolog 1Actionable alterationsTargetable alterationsTreatment optionsClinical trialsHER2 amplificationMetastatic cancerTumor biopsiesHER2 in Breast Cancer
Krishnamurti U, Silverman J. HER2 in Breast Cancer. Advances In Anatomic Pathology 2014, 21: 100-107. PMID: 24508693, DOI: 10.1097/pap.0000000000000015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDrug DesignFemaleGene AmplificationHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesMolecular Targeted TherapyPrecision MedicinePredictive Value of TestsProtein Kinase InhibitorsReceptor, ErbB-2Signal TransductionTreatment OutcomeUp-RegulationConceptsBreast cancerHER2 receptorTime of diagnosisInvasive breast cancerHER2 receptor overexpressionValuable therapeutic targetHER2 biologyASCO guidelinesHER2 statusHER2 amplificationHER2 testingHER2 oncogeneTherapeutic targetReceptor overexpressionHER2CancerMembrane tyrosine kinaseTumor developmentCell proliferationCurrent standardReceptorsTyrosine kinaseChromosome 17q12RecurrenceTherapyThe Clinicopathologic Significance of Centromere 17 Copy Number Alterations in Invasive Breast Carcinoma
Krishnamurti U, Silverman J. The Clinicopathologic Significance of Centromere 17 Copy Number Alterations in Invasive Breast Carcinoma. Advances In Anatomic Pathology 2014, 19: 13-17. DOI: 10.1097/pcr.0000000000000016.Peer-Reviewed Original ResearchAdverse prognostic factorHER2 amplificationBreast cancerPrognostic factorsHuman epidermal growth factor receptor 2 (HER2) oncoproteinCopy number alterationsInvasive breast cancerInvasive breast carcinomaHER2/CEP17HER2 gene amplificationNumber alterationsHER2 copy numberChromosome 17 polysomyCEP17 duplicationMost patientsHER2 overexpressionBreast carcinomaClinicopathologic significanceHER2 2Chromosome 17PatientsCancerProtein overexpressionCopy numberHER2
2013
Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma
Buza N, Hui P. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma. Genes Chromosomes And Cancer 2013, 52: 1178-1186. PMID: 24123408, DOI: 10.1002/gcc.22113.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaHER2/neu gene amplificationNeu gene amplificationSerous carcinomaHER2 protein expressionGene amplificationHeterogeneous tumorsProtein expressionHER2 testing guidelinesHER2 protein overexpressionTumor tissue areaTumor tissue sectionsHER2 statusDifferent tumor samplesHER2 overexpressionHER2 amplificationBreast cancerImmunohistochemical scoreAggressive subclonesCarcinomaClinical testingImmunostaining patternTumor samplesTumor cellsTesting guidelines
2011
PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
Olson E, Flores L, Najita J, Curley C, Jeong J, Murray K, Savoie J, Winer E, Krop I. PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer. Cancer Research 2011, 71: pd05-07-pd05-07. DOI: 10.1158/0008-5472.sabcs11-pd05-07.Peer-Reviewed Original ResearchHER2-positive CTCsMetastatic breast cancerHER2-negative metastatic breast cancerNegative metastatic breast cancerHER2-negative CTCsER-positive diseasePositive CTCsBreast cancerDetectable CTCsLobular histologyPositive diseaseNegative CTCsHER2 amplificationProspective validationHER2-Positive Circulating Tumor CellsHER2-negative breast cancerCEP17 ratioTumor cellsInitial screeningMajority of ptsNegative breast cancerHER2/CEP17 ratioCirculating Tumor CellsDuctal histologyBaseline characteristicsCorrelation of Immunohistochemical Expression of p53 With Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma
Krishnamurti U, Zarineh A, Atem F, Silverman J. Correlation of Immunohistochemical Expression of p53 With Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2011, 19: 28-32. PMID: 20823770, DOI: 10.1097/pai.0b013e3181e9bb6f.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaChromosome 17 polysomyBreast carcinomaHER2 amplificationReceptor negativityPrognostic indicatorNottingham scoreBreast cancerNeck squamous cell carcinomaNonsmall cell lung carcinomaHormone receptor negativityAdverse prognostic indicatorEstrogen receptor negativitySquamous cell carcinomaIndependent prognostic indicatorCell lung carcinomaCell carcinomaP53 positivityBladder carcinomaP53 immunostainingP53 overexpressionImmunohistochemical expressionLung carcinomaCarcinomaP53 expression
2010
Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. British Journal Of Cancer 2010, 102: 1495-1502. PMID: 20461092, PMCID: PMC2869174, DOI: 10.1038/sj.bjc.6605676.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2Tumor cellsHER2 amplificationBreast cancerCTC yieldEpidermal growth factor receptor 2Growth factor receptor 2Breast cancer patientsSignificant discordance existsFactor receptor 2Lung cancer samplesMedian cell countMetastatic tumor cellsCancer patientsLung cancerMetastatic breastMetastatic tumorsPatient CTCsMetastatic cancerMetastatic tissuesBlood samplesReceptor 2Drug AdministrationCell countPatients
2007
Markers predicting clinical benefit in breast cancer from microtubule-targeting agents
Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Annals Of Oncology 2007, 18: xii15-xii20. PMID: 18083698, DOI: 10.1093/annonc/mdm534.Peer-Reviewed Original ResearchConceptsMicrotubule-targeting agentsSubset of patientsEstrogen receptor negativityBreast cancer patientsNon-cross resistanceMicrotubule-associated protein tauMechanism of actionReceptor negativityClinical benefitPatient groupCancer patientsClinical trialsPoor responseHER2 amplificationClinical dataClinical studiesBreast cancerTaxane resistanceBetaIII-tubulinProtein tauP-glycoproteinPharmacogenomic analysisTaxanesLow expressionPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply